Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11801MR)

This product GTTS-WQ11801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11801MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14146MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ4656MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ7376MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ4849MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ5840MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ10739MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ10017MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ6718MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW